Osteoclasts are the sole bone resorbing cells. Heightened activity of these cells under pathological conditions leads to the development of bone loss diseases, such as osteolysis, osteoporosis and rheumatoid arthritis. We have shown previously that TNF strongly induces osteoclastogenesis of pre-osteoclasts and do so through activation of the transcription factor, NF-κB. Most importantly, recent studies have shown that NF-κB is required for the development of osteoclasts. This transcription factor has also been proven as an essential mediator of inflammatory diseases including those related to bone.
INTRODUCTION
Pathologic bone loss is generally attributed to increased recruitment and heightened activity of osteoclasts 1 . These bone-resorbing cells are derived from bone marrowresiding monocyte/macrophages. Differentiation of osteoclasts from their myeloid precursors hinges on recognition, by surface receptors, of two essential cytokines, M-CSF and receptor activator of NF-κB ligand (RANKL) 1 . These factors are sufficient and required to promote osteoclast differentiation, survival and activity [2] [3] [4] [5] [6] [7] . RANKL is secreted by stromal and activated T cells, and transmits signals through binding to its cognate receptor, RANK, which is expressed on the surface of monocytes [7] [8] [9] [10] . Detailed investigation of RANKL signaling revealed that the cytokine activates down stream signals, primarily NF-κB pathway, which is essential for osteoclastogenesis 11 . NF-κB proteins are a family of transcription factors expressed in most cell-types and play an important role in the development of osteoclasts, and regulate immune and inflammatory responses [12] [13] [14] [15] [16] . NF-κB proteins are also involved in protecting cells from undergoing apoptosis in response to cytokine treatment [17] [18] [19] . These events include activation of anti-apoptotic gene products, such as cellular inhibitors of apoptosis (cIAP) [19] [20] [21] [22] [23] . Diverse signal transduction complexes mediate stimulation of NF-κB pathway 19 . The inactive form of the transcription factor exists in the cytoplasm associated with regulatory proteins called IκB 24 4 to DNA and activates target genes 19, 24, 25 . In osteoclast precursor cells, members of the TNF family (RANKL and TNF) are potent activators of the NF-κB pathway and strong inducers of osteoclastogenesis 7, 11, 26, 27 . However, studies from knockout mice showed that in the absence of certain NF-κB molecules, the antiapoptotic effect of NF-κB is hampered. Under these conditions, pro-inflammatory cytokines such as TNF exert a potent pro-apoptotic outcome 20, 22, 23, 28 .
We have shown previously that TNF strongly augments RANKL-primed osteoclastogenesis utilizing mechanisms that involve NF-κB activation 11 . We have also shown that inhibition of NF-κB activation arrests osteoclastogenesis 29 . In the current study, we examined the direct effect of TNF on osteoclasts in which the NF-κB pathway has been blocked. Our findings point out that administration of DN-IκB to osteoclasts and pre-osteoclasts arrests their differentiation and renders them unprotected by virtue of reduced TRAF6, Bcl-X L and cIAP-1 expression. This process is further propagated by TNF. In this system, we document that several apoptotic factors, namely caspase 3, caspase 9, PARP and Bax, are clearly activated. These findings suggest that TNF, in the presence of DN-IκB, induces osteoclast apoptosis through combined inhibition of cIAP-1 and activation of caspases.
MATERIALS and METHODS
Reagents: Antibodies were purchased from Santa Cruz (Santa Cruz, CA). ECL kit was obtained from Pierce (Rockford, IL). TUNEL assay kit was purchased from Oncor (Gaithersburg, MD). Dominant-negative IκBα mutant was generated by N-terminal deletion of residues 1-45 using standard PCR approach. All other chemicals were obtained from Sigma Chemicals (St. Louis, MO). Lysates of unstimulated and Cytochrome c (0.25mg/ml/1hr)-stimulated Jurkat cells used as controls were purchased from Cell Signaling (Beverly, MA).
Animals: C3H/HeN males were purchased from Harlan Industries (Indianapolis, IN).
Cell Culture: osteoclast precursor cells in the form of bone marrow macrophages (BMMs) were isolated as previously described 27 . Briefly, whole bone marrow of 4-6 wk mice was collected and incubated in tissue culture plates, at 37 0 C in 5% CO 2 , in the presence of 10ng/ml M-CSF 27 . After 24 hours in culture, the non-adherent cells were collected and layered on a Ficoll-Hypaque gradient. Cells at the gradient interface were collected and plated in α-MEM, supplemented with 10% heat-inactivated fetal bovine serum, at 37 0 C in 5% CO 2 in the presence of 10ng/ml M-CSF, and plated according to each experimental conditions. Osteoclast generation: osteoclasts were generated by culturing purified precursor cells in the presence of M-CSF and soluble RANKL (10-20 ng/ml each) for 4 days. Bona fide osteoclasts develop on days 3-4 of culture at a point cells are fixed and TRAP-stained or subjected to further treatments. DN-TAT:IκB was added at 5ng/ml on day 3 of culture followed (after 2 hours) by TNF (10 ng/ml). Cultures were then continued for an additional day after which they were processed for immunostaining, immunoblots, or TUNEL assay.
Immunostaining. BMMs were plated on multi-well coverslips in the absence or presence pTAT construct and protein coupling. IκBα constructs were cloned into the pTAT-HA bacterial expression vector previously described by Nagahara et al. 31 which contains a six histidine tag, for easy purification, HA tag for detection followed by the TAT transduction domain and finally, the IκB sequence. The resultant plasmid, pTAT-IκB, was transformed into the DH5α strain of E. Coli. The transformants were screened initially by restriction enzyme mapping. A recombinant containing the correct restriction fragments was then sequenced on both strands. This plasmid was then used to express the 
RESULTS:

Generation and expression of DN-IκB:
IκBα directly binds to and inhibits NF-κB activation. Amino terminal phosphorylation of IκBα facilitates dissociation of NF-κB and subsequent nuclear translocation and activation. To permanently prevent NF-κB activation we utilized a dominant-negative form of IκBα that lacks all possible amino terminal phosphorylation sites. In short, we deleted amino acids 1 through 45 and ligated the remaining 46-317aa into pTAT plasmid for protein expression (not shown). Bacterial expression (Bac) of DN-IκB was then confirmed by immunoblots compared to endogenous expression in macrophages (Mac)(figure 1A). We have successfully utilized the pTAT transduction system to introduce IκBα, STAT6, and other proteins into macrophages and osteoclasts 29, 32 .
DN-IκB localizes to cytoplasmic and nuclear compartments and inhibits NF-κB activation:
Following protein expression and purification the deleted IκBα protein was added to osteoclast cultures for 2 hours. Cells were then fractionated to separate cytoplasmic and nuclear fractions. Immunoblots using anti-HA antibody show that pTAT-IκB is present in both fractions and most abundant in the cytoplasmic compartment (figure 1B). The protein is abundant in cytosols and nuclei within 1 hour and its levels remain elevated up to 24 and 8 hours, respectively (figure 1B). The relative short time of protein retention in the nuclei may be due to nuclear transport and clearance of the protein from this compartment.
Next we examined if the newly transduced DN-IκB is active. To accomplish this goal we tested if DN-IκB is capable of inhibiting TNF-induced NF-κB activation. To this end, cells in the absence or presence of DN-IκB (60 min) were challenged with TNF for 30 minutes. At the end of incubation cells were processed for nuclear extraction and NF-κB activity was measured by electrophoretic mobility shift assay. The results depicted in figure 1C clearly show that DN-IκB potently inhibits TNF-induced activation of NF-κB.
DN-IκB induces apoptosis of osteoclast precursors (macrophages) by TNF:
Marrow-derived macrophages are the precursor cells that in the presence of RANKL and M-CSF undergo osteoclastogenesis in an NF-κB -dependent process. We have shown previously that specific inhibition of NF-κB activation arrests osteoclastogenesis 
DN-IκB renders osteoclasts sensitive to apoptosis by TNF:
NF-IκB is an anti-apoptotic factor essential for osteoclastogenesis and in part mediates the osteoclastogenic properties of TNF. Therefore, we asked if inhibition of NF-κB alters the TNF pro-osteoclastogenic response by RANKL-primed precursors. As we have published previously 11, 29 , TNF mounts a strong osteoclast response when added to preosteoclast cultures ( figure 3A-panel a) The inhibitory effect of DN-IκB on osteoclast formation was obvious when multinucleated TRAP-positive osteoclasts were counted ( Figure 3B ). The data demonstrate that while TNF causes an approximate 5-fold increase in osteoclast number, inclusion of DN-IκB for the same time period (1-day) led to complete inhibition of cytokine-induced osteoclastogenesis. In fact, osteoclast formation in the presence of DN-IκB and TNF was 68% lower than control (p < 0.005), and a statistically not significant 18% below control when treated with DN-IκB alone.
Osteoclast programmed death by DN-IκB and TNF is mediated at least in part by caspase-3, caspase-9 and PARP:
TNF, based on precise and cell-specific machinery, induces pro-and antiapoptotic signals. Evidence from our studies as well as others indicate that under normal circumstances TNF activates NF-κB in primed osteoclast precursors and supports survival of osteoclasts [33] [34] [35] [36] . Inhibition of NF-κB, however, diverts TNF signaling towards a pro-apoptotic avenue. To investigate the mechanisms underlying TNF-mediated apoptosis of osteoclast precursors, RANKL-primed cells were treated with TNF in the absence or presence of the NF-κB inhibitor, IκBα. Cells were then lysed and screened for caspases, the mediators of apoptosis. Our data show that caspases 3, 9 and PARP are activated in cells treated with DN-IκB and TNF (figure 4A-C). Activation is evident by cleavage of the precursor zymogen yielding the active subunits relevant to each protein.
We also observed activation of caspase 9 in the presence of DN-IκB alone, although this activation was not evident in the down stream proteins; namely caspase 3 and PARP. No evidence of activation of caspases 7 and 8 was observed.
DN-IκB facilitates TNF induction of apoptosis by blocking and/or reducing expression of key signaling and pro-survival molecules:
To further examine the mechanism underlying this DN-IκB -dependent, TNF-induced apoptosis, we turned to investigate parallel pathways known to play essential role in signaling cell survival and death. Bax, Bcl-2 and Bcl-X L are members of the Bcl/Bax family that differentially regulate apoptosis. Our findings point out that TNF and DN-IκB significantly increase the expression of Bax ( Figure 5A ). Specifically, TNF and DN-IκB Tat+I, respectively. The TNF-induced increase was partially blocked (74%) by DN-IκB. We also examined the expression of TRAF2 and TRAF6, the later factor is essential for osteoclastogenesis and both proteins are required for osteoclast signaling. While no obvious differences in TRAF2 expression were observed (not shown), DN-IκB reduced TRAF6 expression levels in the absence or presence of TNF (Fig 6B) .
DISCUSSION:
TNF family members, especially RANKL and TNF, utilize mechanisms directed at activation of NF-κB to promote osteoclastogenesis 26, 26, 33 . NF-κB, which itself is essential for osteoclast development 13 , regulates secretion of pro-inflammatory cytokines such as IL-1 and TNF 25, 37, 38 . These cytokines are capable of directly activating the transcription factor, thus establishing a positive feedback cycle that amplifies osteoclastogenesis and associated inflammatory bone loss. This cycle, if not attenuated, leads to a vicious and progressive bone loss. In this regard, evidence from our previous studies point out that TNF exerts a strong osteoclastogenic effect when added to RANKL-primed osteoclast precursors 11 . Heightened osteoclastic activity under these conditions was associated with elevated levels of active NF-κB 11 . These are classical patho-osteoclastogenic features typical for osteolytic diseases. Therefore, TNF induction of NF-κB and subsequent antiapoptotic molecules, such as TRAFs and c-IAPs that antagonize caspases and cell death, protect prolonged osteoclast presence and activity.
These events point to NF-κB as a centerpiece of the patho-osteoclastogenic response.
Switching this transcription factor off, not only arrests the pathologic process, but in the presence of pre-existing pro-inflammatory cytokines, such as TNF, would lead to adverse effects, namely cell-death and reduction of osteoclast numbers. Our data confirm this notion. In this regard, a potent osteoclastic response exerted by TNF ( figure 3 Attenuation of NF-κB activation often leads to a decline in the expression of these cytokines, as we and other have reported in previous studies 33, 35 . Thus, it is conceivable that in the absence of NF-κB -directed endogenous cytokine support for osteoclast differentiation, proliferation and survival, TNF action is averted towards an apoptosissusceptible osteoclast.
DN-IκB, in the absence of TNF, appears to have little or no effect on certain proapoptotic factors. This is evident in the case of caspase 3 and PARP activation (figure 4).
The requirement of TNF to further potentate osteoclast death is likely due to the complexity of the osteoclast survival machinery. Namely, NF-κB unrelated pathways such as ERK and Akt cascades might be able to maintain survival of osteoclasts under physiological conditions 40, 41 . These signaling pathways, however, may not be able to withstand a direct TNF-transmitted apoptotic signal in the absence of NF-κB. In support of this speculation, it is clear that in the presence of TNF, direct administration of DN-IκB seems to facilitate programmed death of osteoclasts. In this regard, it has been shown that treatment of isolated osteoclasts with antisense oligonucleotides to the p65 and p50 subunits of NF-κB or with NF-κB inhibitory agents such as PDTC and TPCK induced apoptosis 42, 43 . Nonetheless, our observations indicate that DN-IκB, in the absence of TNF, is a poor inducer of osteoclast apoptosis. It appears likely that NF-κB inhibition alone compromises cellular protection mechanisms and sets the stage for cytokine-driven programmed cell death. These speculations are in agreement with recent findings by Xing et al 43 , which reported that while p50, and p52 NF-κB subunits are required for osteoclast formation, the absence of these subunits does not cause further apoptosis of Furthermore, cIAPs play a rate-limiting role in NF-κB activation because they are required for upstream activation of the transcription factor in a positive feedback loop.
Moreover, a direct anti-apoptotic effect of these proteins over caspases 3 and 9 has been established [44] [45] [46] . We find that combined treatment of osteoclasts with DN-IκB and TNF reduces c-IAP-1 expression. In what appears as consequential events, NF-κB activation and TRAF6 protein expression, another integral protein required for osteoclastogenesis, are reduced. Thus, it is conceivable that insufficient levels of c-IAP-1 are no longer able to maintain caspases 3 and 9 under control, which leads directly to intensifying the apoptotic event. A plausible explanation for reduced levels of cIAP-1 in the presence of DN-IκB stems from recent findings implicating caspases as partially responsible for cleavage of cIAPs 46, 47 .
In other studies apoptosis of osteoclasts was achieved by exposure to osteoprotegrin (OPG), a soluble TNF receptor family member and RANKL decoy molecule 36 . This protein acts upstream by interfering with RANK/RANKL binding. It is unlikely that OPG plays a part in DN-IκB /TNF-mediated apoptosis of osteoclasts that we describe in this study. This notion is supported by the facts that 1) we used a relatively osteoblast-devoid pure population of osteoclast precursors that do not express or secrete OPG, and 2) RANKL was added exogenously at levels that permit osteoclastogenesis and was maintained continuously throughout the duration of the culture.
In Summary, we have used a convenient tool, namely TAT fusion system that permits efficient delivery of DN-IκB into osteoclasts and their precursors. Our data indicate that DN-IκB attenuates NF-κB activation and in the presence of TNF, which alone is a proosteoclastogenic factor, leads to osteoclast apoptosis. The mechanism of this cell death includes reduction in cIAP-1 expression leading to activation of caspases and up-regulation of Bax/Bcl-X L ratio. These finding may provide the basis for designing strategies to block bone loss due to heightened osteoclast activity. Osteoclasts were formed and treated with TNF, DN-IκB (I) or a combination as described for figure 4. Expression of Bax (A) and Bcl-X L (B) was examined by immunoblots using relevant antibodies. 
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